Seizert Capital Partners LLC Sells 545 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Seizert Capital Partners LLC cut its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,559 shares of the company’s stock after selling 545 shares during the period. Seizert Capital Partners LLC’s holdings in Prestige Consumer Healthcare were worth $4,150,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PBH. Opal Wealth Advisors LLC bought a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth about $26,000. Quest Partners LLC raised its stake in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after buying an additional 424 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock valued at $33,000 after purchasing an additional 208 shares during the last quarter. Gladius Capital Management LP purchased a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter valued at approximately $35,000. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after acquiring an additional 433 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $82.36 on Friday. The firm has a market cap of $4.07 billion, a PE ratio of 20.04, a price-to-earnings-growth ratio of 2.32 and a beta of 0.47. The business has a 50 day moving average price of $73.29 and a 200-day moving average price of $70.25. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. Prestige Consumer Healthcare Inc. has a fifty-two week low of $56.61 and a fifty-two week high of $83.83.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. During the same quarter in the previous year, the business posted $1.07 earnings per share. The firm’s revenue for the quarter was down .9% compared to the same quarter last year. Equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on PBH shares. DA Davidson reaffirmed a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $83.67.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William P’pool sold 8,987 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,935 shares of company stock valued at $2,289,025. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.